Real world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer.

CONCLUSION: Vandetanib and cabozantinib are effective treatment options in the majority of MTC-patients. We hypothesize that the poorer prognosis of cabozantinib-treated patients in our retrospective analysis is most likely due to its use as second line treatment after treatment failure on vandetanib. However, different degrees of efficacy of the two drugs are possible. PMID: 32781914 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research